01324nas a2200277   4500000000100000008004100001260001700042653001500059653001000074653004400084653003000128653001100158653002500169653000900194653001600203653001600219100001500235700001400250700001400264245006500278300001100343490000700354050003200361520063900393022001401032       1990                            d  c1990 Jul-Sep10aAdolescent10aAdult10aAnti-Inflammatory Agents, Non-Steroidal10aDrug Therapy, Combination10aHumans10aLeprosy, lepromatous10aMale10aMiddle Aged10aThalidomide1 aJadhav V H1 aPatki A H1 aMehta J M00aThalidomide in type-2 lepra reaction--a clinical experience.  a316-200 v62  aInfolep Library - available3 a<p>A clinical experience of using thalidomide in type-2 lepra reaction (ENL) in 90 male patients--57 with lepromatous leprosy (LL) and 33 with borderline lepromatous leprosy (BL)--is described. All the patients responded well although some took a longer time to improve. No major side effects were observed except for giddiness in 10 and gastrointestinal upsets in 7 patients. Thalidomide thus appears to be a very effective drug in the treatment of severe type-2 lepra reaction and apart from its historically well-documented embryopathic effects, does not seem to have any other serious side effects in the patients under study.</p>  a0254-9395